与犹他州的Nusano公司达成为期三年的铜-67供货协议,用于癌症治疗发展。 Clarity Pharmaceuticals secures a three-year copper-67 supply deal with Utah’s Nusano for cancer treatment development.

Cleary制药公司与以犹他州为基地的Nusano公司签订了一项为期三年的铜-67(一种治疗癌症的放射性同位素)供应协定。 Clarity Pharmaceuticals has secured a three-year supply agreement with Utah-based Nusano, Inc., for copper-67, a cancer-treating radioisotope. Nusano的新犹他州设施定于2025年底启用,将使用加速器技术从2026年年中开始生产铜-67,为依赖反应堆的方法提供可缩放的、以美国为基地的替代方法。 Nusano’s new Utah facility, set to open in late 2025, will use accelerator-based technology to produce copper-67 starting in mid-2026, offering a scalable, U.S.-based alternative to reactor-dependent methods. 该伙伴关系加强了Clarity的国内供应网络,并支持其牵头产品67Cu-SAR-BisPSMA与FDA快车道识别进行前列腺癌症临床开发。 The partnership strengthens Clarity’s domestic supply network and supports its lead product, 67Cu-SAR-bisPSMA, in clinical development for prostate cancer with FDA Fast Track Designation. 协议包括自动续签和标准取消条件。 The agreement includes automatic renewals and standard cancellation terms. 明确性强调,需要可靠的同位素供应,以预先试验和商业化,尽管该产品仍然是调查性的,不能保证批准或市场供应。 Clarity emphasizes the need for reliable isotope supply to advance trials and commercialization, though the product remains investigational with no guarantee of approval or market availability.